{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:34:56Z","timestamp":1760189696267,"version":"3.37.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T00:00:00Z","timestamp":1567036800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T00:00:00Z","timestamp":1567036800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s00432-019-03014-x","type":"journal-article","created":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T12:13:22Z","timestamp":1567080802000},"page":"2823-2834","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Reduced intensity conditioning regimens including alkylating chemotherapy do not alter survival outcomes after allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia compared to low-intensity non-myeloablative conditioning"],"prefix":"10.1007","volume":"145","author":[{"name":"the CLL subcommittee, Chronic Malignancies Working Party","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels Smedegaard","family":"Andersen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Bornh\u00e4user","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Gramatzki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Dreger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonin","family":"Vitek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michal","family":"Karas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauricette","family":"Michallet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"van Gelder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja","family":"Henseler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liesbeth C.","family":"de Wreede","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Sch\u00f6nland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2780-2981","authenticated-orcid":false,"given":"Johannes","family":"Schetelig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,29]]},"reference":[{"key":"3014_CR1","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, Apperley J, Slavin S, Pasquini M, Sandmaier BM, Barrett J, Blaise D, Lowski R, Horowitz M (2009) Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transpl 15:1628\u20131633","journal-title":"Biol Blood Marrow Transpl"},{"key":"3014_CR2","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/leu.2012.228","volume":"27","author":"JR Brown","year":"2013","unstructured":"Brown JR, Kim HT, Armand P, Cutler C, Fisher DC, Ho V, Koreth J, Ritz J, Wu C, Antin JH, Soiffer RJ, Gribben JG, Alyea EP (2013) Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome. Leukemia 27:362\u2013369","journal-title":"Leukemia"},{"key":"3014_CR3","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1200\/JCO.2011.37.4108","volume":"30","author":"K Cwynarski","year":"2012","unstructured":"Cwynarski K, van Biezen A, de Wreede L, Stilgenbauer S, Bunjes D, Metzner B, Koza V, Mohty M, Remes K, Russell N, Nagler A, Scholten M, de Witte T, Sureda A, Dreger P (2012) Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter\u2019s syndrome): a retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 30:2211\u20132217","journal-title":"J Clin Oncol"},{"key":"3014_CR4","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1182\/asheducation-2017.1.346","volume":"2017","author":"MS Davids","year":"2017","unstructured":"Davids MS (2017) How should we sequence and combine novel therapies in CLL? Hematol Am Soc Hematol Educ Progr 2017:346\u2013353","journal-title":"Hematol Am Soc Hematol Educ Progr"},{"key":"3014_CR5","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/j.bbmt.2008.09.001","volume":"14","author":"J Delgado","year":"2008","unstructured":"Delgado J, Pillai S, Benjamin R, Caballero D, Martino R, Nathwani A, Lovell R, Thomson K, Perez-Simon JA, Sureda A, Kottaridis P, Vazquez L, Peggs K, Sierra J, Milligan D, Mackinnon S (2008) The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia. Biol Blood Marrow Transpl 14:1288\u20131297","journal-title":"Biol Blood Marrow Transpl"},{"key":"3014_CR6","first-page":"1901","volume":"78","author":"G Dighiero","year":"1991","unstructured":"Dighiero G, Travade P, Chevret S, Fenaux P, Chastang C, Binet JL (1991) B-cell chronic lymphocytic leukemia: present status and future directions. French Cooper Group CLL Blood 78:1901\u20131914","journal-title":"French Cooper Group CLL Blood"},{"key":"3014_CR7","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","volume":"343","author":"H Dohner","year":"2000","unstructured":"Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, Dohner K, Bentz M, Lichter P (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343:1910\u20131916","journal-title":"N Engl J Med"},{"key":"3014_CR8","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1038\/sj.leu.2403745","volume":"19","author":"P Dreger","year":"2005","unstructured":"Dreger P, Brand R, Milligan D, Corradini P, Finke J, Lambertenghi Deliliers G, Martino R, Russell N, van Biezen A, Michallet M, Niederwieser D (2005) Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis. Leukemia 19:1029\u20131033","journal-title":"Leukemia"},{"key":"3014_CR9","first-page":"12","volume":"21","author":"P Dreger","year":"2007","unstructured":"Dreger P, Corradini P, Kimby E, Michallet M, Milligan D, Schetelig J, Wiktor-Jedrzejczak W, Niederwieser D, Hallek M, Montserrat E (2007) Chronic Leukemia Working Party of the E. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus Leukemia 21:12\u201317","journal-title":"Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus Leukemia"},{"key":"3014_CR10","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1182\/blood-2018-01-826008","volume":"132","author":"P Dreger","year":"2018","unstructured":"Dreger P, Ghia P, Schetelig J, van Gelder M, Kimby E, Michallet M, Moreno C, Robak T, Stilgenbauer S, Montserrat E (2018a) High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies. Blood 132:892\u2013902","journal-title":"Blood"},{"key":"3014_CR11","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41409-018-0207-4","volume":"54","author":"P Dreger","year":"2018","unstructured":"Dreger P, Michallet M, Bosman P, Dietrich S, Sobh M, Boumendil A, Nagler A, Scheid C, Cornelissen J, Niederwieser D, Muller L, Vandenberghe E, Scortechini I, Schoemans H, Andersen NS, Finke J, Russo D, Ljungman P, Passweg J, van Gelder M, Durakovic N, Labussiere-Wallet H, Berg T, Wulf G, Bethge W, Bunjes D, Stilgenbauer S, Canepari ME, Schaap M, Fox CP, Kroger N, Montoto S, Schetelig J (2018b) Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties. Bone Marrow Transpl 54:44","journal-title":"Bone Marrow Transpl"},{"key":"3014_CR12","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S1470-2045(14)70161-5","volume":"15","author":"B Glass","year":"2014","unstructured":"Glass B, Hasenkamp J, Wulf G, Dreger P, Pfreundschuh M, Gramatzki M, Silling G, Wilhelm C, Zeis M, Gorlitz A, Pfeiffer S, Hilgers R, Truemper L, Schmitz N (2014) Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial. Lancet Oncol 15:757\u2013766","journal-title":"Lancet Oncol"},{"key":"3014_CR13","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1182\/blood-2014-02-558767","volume":"124","author":"L Gragert","year":"2014","unstructured":"Gragert L, Fingerson S, Albrecht M, Maiers M, Kalaycio M, Hill BT (2014) Fine-mapping of HLA associations with chronic lymphocytic leukemia in US populations. Blood 124:2657\u20132665","journal-title":"Blood"},{"key":"3014_CR14","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1002\/1097-0142(197003)25:3<523::AID-CNCR2820250305>3.0.CO;2-E","volume":"25","author":"RE Johnson","year":"1970","unstructured":"Johnson RE (1970) Total body irradiation of chronic lymphocytic leukemia: incidence and duration of remission. Cancer 25:523\u2013530","journal-title":"Cancer"},{"key":"3014_CR15","doi-asserted-by":"publisher","first-page":"5530","DOI":"10.1182\/blood-2008-01-136242","volume":"111","author":"IF Khouri","year":"2008","unstructured":"Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS, Medeiros LJ, Fayad L, Samaniego F, Alousi A, Anderlini P, Couriel D, de Lima M, Giralt S, Neelapu SS, Ueno NT, Samuels BI, Hagemeister F, Kwak LW, Champlin RE (2008) Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 111:5530\u20135536","journal-title":"Blood"},{"key":"3014_CR16","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1182\/blood-2017-04-775841","volume":"130","author":"I Kramer","year":"2017","unstructured":"Kramer I, Stilgenbauer S, Dietrich S, Bottcher S, Zeis M, Stadler M, Bittenbring J, Uharek L, Scheid C, Hegenbart U, Ho A, Hallek M, Kneba M, Schmitz N, Dohner H, Dreger P (2017) Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial. Blood 130:1477\u20131480","journal-title":"Blood"},{"key":"3014_CR17","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1182\/blood-2016-05-716977","volume":"128","author":"AR Mato","year":"2016","unstructured":"Mato AR, Nabhan C, Barr PM, Ujjani CS, Hill BT, Lamanna N, Skarbnik AP, Howlett C, Pu JJ, Sehgal AR, Strelec LE, Vandegrift A, Fitzpatrick DM, Zent CS, Feldman T, Goy A, Claxton DF, Bachow SH, Kaur G, Svoboda J, Nasta SD, Porter D, Landsburg DJ, Schuster SJ, Cheson BD, Kiselev P, Evens AM (2016) Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience. Blood 128:2199\u20132205","journal-title":"Blood"},{"key":"3014_CR18","doi-asserted-by":"publisher","first-page":"311","DOI":"10.7326\/0003-4819-124-3-199602010-00005","volume":"124","author":"M Michallet","year":"1996","unstructured":"Michallet M, Archimbaud E, Bandini G, Rowlings PA, Deeg HJ, Gahrton G, Montserrat E, Rozman C, Gratwohl A, Gale RP (1996) HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. European Group for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry. Ann Intern Med 124:311\u2013315","journal-title":"Ann Intern Med"},{"key":"3014_CR19","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.exphem.2012.10.008","volume":"41","author":"M Michallet","year":"2013","unstructured":"Michallet M, Socie G, Mohty M, Sobh M, Bay JO, Morisset S, Labussiere-Wallet H, Tabrizi R, Milpied N, Bordigoni P, El-Cheikh J, Blaise D (2013) Rituximab, fludarabine, and total body irradiation as conditioning regimen before allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukemia: long-term prospective multicenter study. Exp Hematol 41:127\u2013133","journal-title":"Exp Hematol"},{"key":"3014_CR20","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1182\/blood-2003-12-4321","volume":"104","author":"M Ritgen","year":"2004","unstructured":"Ritgen M, Stilgenbauer S, Von Neuhoff N, Humpe A, Bruggemann M, Pott C, Raff T, Krober A, Bunjes D, Schlenk R, Schmitz N, Dohner H, Kneba M, Dreger P (2004) Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy chain gene status: implications of minimal residual disease measurement with quantitative PCR. Blood 104:2600\u20132602","journal-title":"Blood"},{"key":"3014_CR21","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.bbmt.2013.11.032","volume":"20","author":"M Sabloff","year":"2014","unstructured":"Sabloff M, Sobecks RM, Ahn KW, Zhu X, de Lima M, Brown JR, Inamoto Y, Holland HK, Aljurf MD, Laughlin MJ, Kamble RT, Hsu JW, Wirk BM, Seftel M, Lewis ID, Arora M, Alyea EP, Kalaycio ME, Cortes J, Maziarz RT, Gale RP, Saber W (2014) Does total body irradiation conditioning improve outcomes of myeloablative human leukocyte antigen-identical sibling transplantations for chronic lymphocytic leukemia? Biol Blood Marrow Transpl 20:421\u2013424","journal-title":"Biol Blood Marrow Transpl"},{"key":"3014_CR22","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","volume":"17","author":"M Schemper","year":"1996","unstructured":"Schemper M, Smith TL (1996) A note on quantifying follow-up in studies of failure time. Control Clin Trials 17:343\u2013346","journal-title":"Control Clin Trials"},{"key":"3014_CR23","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1200\/JCO.2003.12.011","volume":"21","author":"J Schetelig","year":"2003","unstructured":"Schetelig J, Thiede C, Bornhauser M, Schwerdtfeger R, Kiehl M, Beyer J, Sayer HG, Kroger N, Hensel M, Scheffold C, Held TK, Hoffken K, Ho AD, Kienast J, Neubauer A, Zander AR, Fauser AA, Ehninger G, Siegert W (2003) Cooperative German Transplant Study G. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol 21:2747\u20132753","journal-title":"J Clin Oncol"},{"key":"3014_CR24","first-page":"4576","volume":"130","author":"J Schetelig","year":"2017","unstructured":"Schetelig J, Chevallier P, Van Gelder M, Hoek J, Hermine O, Chakraverty R, Browne P, Milpied N, Malagola M, Socie G, Delgado J, Deconinck E, Damaj G, Cordonnier C, Beelen DW, Nguyen S, Nikolousis E, Brecht A, Mayer J, Hunault M, Bittenbring JT, Thieblemont C, Lepr\u00eatre S, de Wreede LC, Dreger P, Kr\u00f6ger N (2017a) Remission status at transplantation and treatment history determine the survival chances of patients after allogeneic hematopoietic stem cell transplantation for chronic lymphocytic leukemia who had received pre-treatment with idelalisib: a report from the EBMT chronic malignancies working party. Blood 130:4576","journal-title":"Blood"},{"key":"3014_CR25","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/bjh.14791","volume":"178","author":"J Schetelig","year":"2017","unstructured":"Schetelig J, de Wreede LC, Andersen NS, Moreno C, van Gelder M, Vitek A, Karas M, Michallet M, Machaczka M, Gramatzki M, Beelen D, Finke J, Delgado J, Volin L, Passweg J, Dreger P, Schaap N, Wagner E, Henseler A, van Biezen A, Bornhauser M, Iacobelli S, Putter H, Schonland SO, Kroger N (2017b) Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective analysis from the European Society for Blood and Marrow Transplantation (EBMT). Br J Haematol 178:521\u2013533","journal-title":"Br J Haematol"},{"key":"3014_CR26","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/bmt.2016.329","volume":"52","author":"J Schetelig","year":"2017","unstructured":"Schetelig J, de Wreede LC, van Gelder M, Andersen NS, Moreno C, Vitek A, Karas M, Michallet M, Machaczka M, Gramatzki M, Beelen D, Finke J, Delgado J, Volin L, Passweg J, Dreger P, Henseler A, van Biezen A, Bornhauser M, Schonland SO, Kroger N (2017c) Risk factors for treatment failure after allogeneic transplantation of patients with CLL: a report from the European Society for Blood and Marrow Transplantation. Bone Marrow Transpl 52:552\u2013560","journal-title":"Bone Marrow Transpl"},{"key":"3014_CR27","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1111\/bjh.15181","volume":"184","author":"J Schetelig","year":"2018","unstructured":"Schetelig J, Link CS, Stuhler G, Wagner EM, Hanel M, Kobbe G, Bottcher S, Kreuzer KA, Middeke JM, Sockel K, Teipel R, von Bonin M, Stolzel F, Kramer M, Stilgenbauer S, Hallek M, Bornhauser M (2018) Anti-CD20 immunotherapy as a bridge to tolerance, after allogeneic stem cell transplantation for patients with chronic lymphocytic leukaemia: results of the CLLX4 trial. Br J Haematol 184:833","journal-title":"Br J Haematol"},{"key":"3014_CR28","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1038\/leu.2011.30","volume":"25","author":"N Shah","year":"2011","unstructured":"Shah N, Decker WK, Lapushin R, Xing D, Robinson SN, Yang H, Parmar S, Tung SS, O\u2019Brien S, Fernandez-Vina M, Shpall EJ, Wierda WG (2011) HLA homozygosity and haplotype bias among patients with chronic lymphocytic leukemia: implications for disease control by physiological immune surveillance. Leukemia 25:1036\u20131039","journal-title":"Leukemia"},{"key":"3014_CR29","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1016\/j.bbmt.2014.05.020","volume":"20","author":"RM Sobecks","year":"2014","unstructured":"Sobecks RM, Leis JF, Gale RP, Ahn KW, Zhu X, Sabloff M, de Lima M, Brown JR, Inamoto Y, Hale GA, Aljurf MD, Kamble RT, Hsu JW, Pavletic SZ, Wirk B, Seftel MD, Lewis ID, Alyea EP, Cortes J, Kalaycio ME, Maziarz RT, Saber W (2014) Outcomes of human leukocyte antigen-matched sibling donor hematopoietic cell transplantation in chronic lymphocytic leukemia: myeloablative versus reduced-intensity conditioning regimens. Biol Blood Marrow Transpl 20:1390\u20131398","journal-title":"Biol Blood Marrow Transpl"},{"key":"3014_CR30","doi-asserted-by":"publisher","first-page":"3819","DOI":"10.1200\/JCO.2005.04.569","volume":"23","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Sandmaier BM, Storer BE, Stuart MJ, Hegenbart U, Agura E, Chauncey TR, Leis J, Pulsipher M, McSweeney P, Radich JP, Bredeson C, Bruno B, Langston A, Loken MR, Al-Ali H, Blume KG, Storb R, Maloney DG (2005) Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol 23:3819\u20133829","journal-title":"J Clin Oncol"},{"key":"3014_CR31","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1182\/blood-2007-07-098483","volume":"111","author":"ML Sorror","year":"2008","unstructured":"Sorror ML, Storer BE, Maloney DG, Sandmaier BM, Martin PJ, Storb R (2008a) Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood 111:446\u2013452","journal-title":"Blood"},{"key":"3014_CR32","doi-asserted-by":"publisher","first-page":"4912","DOI":"10.1200\/JCO.2007.15.4757","volume":"26","author":"ML Sorror","year":"2008","unstructured":"Sorror ML, Storer BE, Sandmaier BM, Maris M, Shizuru J, Maziarz R, Agura E, Chauncey TR, Pulsipher MA, McSweeney PA, Wade JC, Bruno B, Langston A, Radich J, Niederwieser D, Blume KG, Storb R, Maloney DG (2008b) Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol 26:4912\u20134920","journal-title":"J Clin Oncol"},{"key":"3014_CR33","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/j.1365-2141.1957.tb05789.x","volume":"3","author":"D Turesson","year":"1957","unstructured":"Turesson D (1957) Myleran treatment in chronic granulocytic leukaemia. Br J Haematol 3:220\u2013226","journal-title":"Br J Haematol"},{"key":"3014_CR34","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","volume":"35","author":"CJ Turtle","year":"2017","unstructured":"Turtle CJ, Hay KA, Hanafi LA, Li D, Cherian S, Chen X, Wood B, Lozanski A, Byrd JC, Heimfeld S, Riddell SR, Maloney DG (2017) Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib. J Clin Oncol 35:3010\u20133020","journal-title":"J Clin Oncol"},{"key":"3014_CR35","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/bmt.2016.282","volume":"52","author":"M van Gelder","year":"2017","unstructured":"van Gelder M, de Wreede LC, Bornhauser M, Niederwieser D, Karas M, Anderson NS, Gramatzki M, Dreger P, Michallet M, Petersen E, Bunjes D, Potter M, Beelen D, Cornelissen JJ, Yakoub-Agha I, Russell NH, Finke J, Schoemans H, Vitek A, Urbano-Ispizua A, Blaise D, Volin L, Chevallier P, Caballero D, Putter H, van Biezen A, Henseler A, Schonland S, Kroger N, Schetelig J (2017) Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation. Bone Marrow Transpl 52:372\u2013380","journal-title":"Bone Marrow Transpl"},{"key":"3014_CR36","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.bbmt.2008.04.003","volume":"14","author":"D Weisdorf","year":"2008","unstructured":"Weisdorf D, Spellman S, Haagenson M, Horowitz M, Lee S, Anasetti C, Setterholm M, Drexler R, Maiers M, King R, Confer D, Klein J (2008) Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival. Biol Blood Marrow Transpl 14:748\u2013758","journal-title":"Biol Blood Marrow Transpl"},{"key":"3014_CR37","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1182\/blood-2009-05-224071","volume":"114","author":"T Zenz","year":"2009","unstructured":"Zenz T, Habe S, Denzel T, Mohr J, Winkler D, Buhler A, Sarno A, Groner S, Mertens D, Busch R, Hallek M, Dohner H, Stilgenbauer S (2009) Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood 114:2589\u20132597","journal-title":"Blood"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-019-03014-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-019-03014-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-019-03014-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T23:32:40Z","timestamp":1598571160000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-019-03014-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,29]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["3014"],"URL":"https:\/\/doi.org\/10.1007\/s00432-019-03014-x","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"type":"print","value":"0171-5216"},{"type":"electronic","value":"1432-1335"}],"subject":[],"published":{"date-parts":[[2019,8,29]]},"assertion":[{"value":"12 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare to have no conflict of interest with the issue addressed with this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This is a retrospective registry study of the European Society of Blood and Marrow Transplantation (EBMT). Patients were not exposed to study procedures or addional assessments. The study was approved by the internal study board of the Chronic Malignancies Working Party of EBMT. EBMT Registry data were analyzed in full compliance with the Society\u2019s institutional standards. All patients have consented in the use of their medical data to advance hematopoietic cell transplantation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}